CERYVYN THERAPEUTICS LIMITED ADR
WKN: A2QEW7 | ISIN: US68386J2087 | Ticker-Symbol: UKJ2Siehe auch CERYVYN THERAPEUTICS LIMITED
München
08.07.26 | 08:05
0,088 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | OPTHEA LIMITED: Change of Company Name, ASX Code and Registered Office | 1 | ASX | ||
| 03.07. | OPTHEA LIMITED: Results of EGM | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Change of Director's Interest Notice - JL | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Notification regarding unquoted securities - OPT | - | ASX | ||
| 24.06. | OPTHEA LIMITED: Becoming a substantial holder | - | ASX | ||
| 22.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| CERYVYN THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 19.06. | OPTHEA LIMITED: Change of Director's Interest Notice - KC & LG | - | ASX | ||
| 18.06. | Dr Boreham's Crucible: Opthea seeks a second act with rare lung disease program | 1 | Stockhead | ||
| 18.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 17.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 16.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Revised Webinar Details and Investor Presentation | - | ASX | ||
| 11.06. | OPTHEA LIMITED: Becoming a substantial holder | - | ASX | ||
| 10.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 09.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 09.06. | OPTHEA LIMITED: Notice of Market Update | - | ASX | ||
| 05.06. | OPTHEA LIMITED: Change in substantial holding | 1 | ASX | ||
| 05.06. | HotCopper Highlights Wk 23: DXN jumps +600%; NST read the riot act, Opthea, 14D & more | 1 | The Market Online Australia | ||
| 04.06. | Why IperionX, Northern Star, Opthea, and Superloop shares are tumbling today | 28 | The Motley Fool Australia |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 10,390 | -1,89 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 7,780 | +21,56 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.07.2026 | The following instruments on XETRA do have their first trading 03.07.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.07.2026
Aktien
1 JP3100020001 Archion Corp.
2 US73110F1003... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 68,62 | -0,29 % | Halozyme Therapeutics, Inc.: Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 | SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 6,400 | +0,31 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| GLOW LIFETECH | 0,020 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Achieves Warrant-Free Capital Structure Following Elimination of 70 Million Warrants and 20% Reduction in Fully Diluted Shares | Toronto, Ontario--(Newsfile Corp. - June 2, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that all of its outstanding 8,900,000... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 254,60 | -2,08 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,380 | -5,56 % | BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model | Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 4,126 | -2,96 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,360 | -2,89 % | Biocytogen und Whitehawk Therapeutics vereinbaren weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten (ADC) | Biocytogen (SSE: 688796; HKEX: 02315) und Whitehawk Therapeutics, Inc. ("Whitehawk", Nasdaq: WHWK) gaben heute eine weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,360 | -0,84 % | Ovid Therapeutics Inc.: Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development | Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting... ► Artikel lesen | |
| COCRYSTAL | 0,835 | -3,47 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer | BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 9,575 | -0,73 % | INNOVENT BIO (01801): NEXT DAY DISCLOSURE RETURN | ||
| GEOVAX LABS | 1,190 | +1,71 % | EQS-News: GeoVax, Inc.: GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness... ► Artikel lesen |
Das Unternehmen CERYVYN THERAPEUTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,088 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERYVYN THERAPEUTICS LIMITED ADR finden Sie auf Wallstreet Online.